<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880798</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-BCH-124I</org_study_id>
    <nct_id>NCT04880798</nct_id>
  </id_info>
  <brief_title>Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer</brief_title>
  <official_title>Effect of Thyrotropin Level on Iodine Uptake: a Prospective 124I PET/CT Study in Metastatic Differentiated Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Distant metastases is the leading cause of differentiated thyroid cancer-related death.&#xD;
      Radioactive iodine (RAI) treatment is the most effective therapy for RAI-avid metastatic&#xD;
      differentiated thyroid cancer (DTC). It is well known that the efficacy of RAI therapy is&#xD;
      depend on the sodium-iodide symporter protein, which can be synthesized by elevated&#xD;
      thyrotropin stimulation. Therefore, thyrotropin stimulation before RAI treatment to ensure&#xD;
      sufficient uptake of RAI has been a long-established procedure. According to some&#xD;
      observational studies, thyrotropin of 25-30 μIU/mL has been adopted as the standard care&#xD;
      protocol. However, whether thyrotropin of 25-30 μIU/mL is enough to stimulate iodine uptake&#xD;
      in metastatic lesions remains unknown. In this study, the investigators aim to address the&#xD;
      effect of thyrotropin on iodine uptake in metastatic DTC during levothyroxine withdrawal by&#xD;
      two times 124I PET/CT scans on different endogenous thyrotropin levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is estimated that 10 patients who met the study criteria will be enrolled. All patients&#xD;
      underwent twice 124I PET/CT scans in Beijing Cancer Hospital. The first 124I PET/CT was&#xD;
      prepared with endogenous thyrotropin 30±10 μIU/mL, the second 124I PET/CT was prepared with&#xD;
      endogenous thyrotropin &gt;100 μIU/mL. The RAI-avidity of the metastases was assessed twice&#xD;
      along with the levothyroxine withdrawal by 124I PET/CT scans.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of thyrotropin level on iodine uptake in metastatic DTC lesions on twice 124I PET/CT.</measure>
    <time_frame>1 month</time_frame>
    <description>SUV metrics of RAI-avid metastatic DTC lesions on twice 124I PET/CT.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Differentiated Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>124I PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All eligible patients will be allocated to this arm (single-arm study).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>124I PET/CT</intervention_name>
    <description>The first 124I PET/CT was prepared with endogenous thyrotropin 30±10 μIU/mL, and the second 124I PET/CT was prepared with endogenous thyrotropin &gt;100 μIU/mL. The RAI-avidity of the metastases was assessed twice along with the levothyroxine withdrawal by 124I PET/CT scans.</description>
    <arm_group_label>124I PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients underwent total thyroidectomy.&#xD;
&#xD;
          2. Patients were diagnosed with differentiated thyroid cancer by postoperative&#xD;
             pathological examination.&#xD;
&#xD;
          3. Distant metastases confirmed by CT etc.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or lactation.&#xD;
&#xD;
          2. Significant hepatic or renal dysfunction;&#xD;
&#xD;
          3. Unable to lie flat, still or tolerate a PET scan.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yansong Lin, Prof</last_name>
    <phone>86-010-69155610</phone>
    <email>linyansong1968@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhi Yang, Prof</last_name>
    <phone>86-010-88196196</phone>
    <email>pekyz@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan-Song Lin</last_name>
    </contact>
    <contact_backup>
      <phone>8601069155610</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi Yang, Prof</last_name>
      <phone>86-010-88196196</phone>
      <email>pekyz@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Yansong Lin</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>differentiated thyroid cancer</keyword>
  <keyword>pulmonary metastases</keyword>
  <keyword>bone metastases</keyword>
  <keyword>thyrotropin</keyword>
  <keyword>thyroid stimulating hormone</keyword>
  <keyword>124I PET/CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

